Dr. Ronald Desrosiers of the New England Primate Research Center at the Harvard Medical School provides his opinions on the HIV-1deltakURNe vaccine strain. Dr. Desrosiers explains what this strain represents and how it was chosen for live-attenuated HIV vaccine human safety trials. Further, Desrosiers discusses the balance in using highly attenuated vaccines and protection effectiveness, whether it is possible for the vaccine strain to revert to a disease-causing form, the possibility of transmission of a vaccine virus to unvaccinated individuals, and the issue of cancer development through insertional mutagenesis.
|Original language||English (US)|
|Number of pages||2|
|Journal||Journal of the International Association of Physicians in AIDS Care|
|State||Published - Mar 1998|
ASJC Scopus subject areas